On the stock market since 2018, it operates in the world of health and science. It has 601 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 10% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 39% below its peak. The market has trimmed its expectations for the company.
Sales run at $247M a year. A small number, but proof the product has real buyers.
There is $981M in the vault; even if every debt were paid off, $869M would remain.
The average analyst price target is $39.17 — 33% above today’s price.
A loss of $353M against $247M in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 19/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 20/100.
On our five-subject report card, RCUS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RCUS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (34/100) says the stock isn’t cheap.